Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 May 2021 | Story Leonie Bolleurs | Photo Leonie Bolleurs
The Maloti-Drakensberg is known as the ’water tower of Southern Africa’, as it is the largest provider of fresh water in the region. If the alpine system collapses, the water production will be detrimentally impacted.

The Afromontane Research Unit (ARU) of the University of the Free State, based in Phuthaditjhaba South Africa, is partnering with several institutions of higher learning, relevant forums, foundations, and policy makers in Africa in an attempt to expand its alpine research.

The research unit is joining forces with the University of Helsinki (Finland) and the National University of Lesotho (NUL) for a National Research Foundation (NRF) award to the University of Pretoria on using fine-scale functional and compositional variation in alpine plants to predict the impact of climate change. According to Dr Ralph Clark, Director of the ARU, this project will expand understanding of the ecology of the alpine zone in the Maloti-Drakensberg, and its similarity (or dissimilarity) with other alpine and tundra environments. 

First step towards sustainability and restoration

A complimentary visit by Alex Hickman, Chair of the African Mountain Research Foundation (AMRF), to the Bvumba Mountains in Zimbabwe, the ARU, and Afriski, laid the psychological foundations for the first two AMRF mountain observatories, as well as gaining support from Afriski as a focus area for alpine studies in the Maloti-Drakensberg. 

Dr Clark explains that the Maloti-Drakensberg is known as the ’water tower of Southern Africa’, as it is the largest provider of fresh water in the region. “The alpine system is critical to this water provisioning function but is under tremendous pressure from intense communal rangeland degradation. If the alpine system collapses, the water production will be detrimentally impacted,” he says.

“Understanding this alpine system holistically is the first step to sustainability and restoration in a social-ecological paradigm,” he adds.

Building capacity for mountain research

The ARU is leading two University Staff Doctorate Programmes (USDPs), both in partnership with the University of Venda, which supports 20 young academics to achieve their doctorates. Dr Clark says while doctoral topics are diverse, they are both focused on building capacity for mountain research in Southern Africa – including the mountain cities of Phuthaditjhaba and Thohoyandou. 

According to him, there are three partners from the United States of America (Appalachian and Colorado State Universities, and the University of Montana) and one partner from the United Kingdom (University of the Highlands and Islands) in the USDPs. Prof Geofrey Mukwada from the Department of Geography and Dr Grey Magaiza from the Department of Sociology are co-ordinating the USDPs.  

The ARU has also attracted one of Southern Africa’s top biodiversity scientists, Prof Peter Taylor, who started at the ARU Department of Zoology and Entomology in January 2021. Dr Clark believes that Prof Taylor – an NRF B3-rated researcher with an H-index of 34 who handed over his SARChI Research Chair to join the ARU – will catapult the ARU to a higher level of regional connectivity (notably with Angola), research outputs, and internal mentoring capacity. Prof Taylor, described as a mammologist and evolutionary biologist, specialises in the systematics, ecology, conservation, and ecosystem services and disservices of small mammals, in particular rodents, bats, and shrews.

Collaboration with two SARChI chairs

The ARU also collaborates with two Department of Science and Innovation NRF centres of excellence (Centre for Biological Control at Rhodes University, and the Centre for Invasion Biology at Stellenbosch University) and one SARChI Chair (Ecosystem Health and Biodiversity in KwaZulu-Natal and the Eastern Cape) on various non-native species in Southern African mountains. 

“The rose (Rosaceae) and grass (Poaceae) plant families are particular problem groups in our mountains. For example, firethorns (Pyracantha species) invade native grassland, taking over valuable grazing land and displacing indigenous species. Nassella grasses similarly displace natural rangeland and render farms unusable – if unchecked, the cost of controlling the nassella can exceed the value of the property. Our research seeks to understand the reproductive ecology of these species better, as well as best practice management,” explains Dr Clark.

In addition, the ARU has an ongoing collaboration on montane pollination systems with the SARChI Chair in Evolutionary Biology at the University of KwaZulu-Natal and the University of Cape Town. Dr Sandy-Lynn Steenhuisen in the Department of Plant Sciences is the ARU champion for both programmes. 

Connecting with policy makers in Lesotho

As of the first quarter in 2020, the ARU was invited to sit on the Maloti-Drakensberg Transfrontier Programme (MDTP): Biodiversity Sub-Committee. This opportunity enables the ARU to connect directly with high-level policy makers in Lesotho and South Africa, and to increase its reach for science-policy connections across the Maloti-Drakensberg region. 

Dr Clark states that partnerships under the MDTP can assist in achieving the ARU’s research goal of ‘the sustainable development of the Maloti-Drakensberg’. According to him, the ARU has proposed a focus in the MDTP on the degradation of the Mont-aux-Sources area. A qualitative site assessment by Dr Clark has, among others, also led to a book chapter being submitted in 2021.

The ARU is also extending its reach to include research on montane wetlands. Together with BirdLife South Africa, they have finalised a memorandum of understanding around montane wetland research, offering the potential for partnering to survey poorly studied montane wetlands for rare biodiversity, notably key endangered bird species. 

Dr Clark says the montane wetland bio-acoustic network has been strengthened through Dr Peter Chatanga (NUL) landing a British Ecological Society grant for bio-acoustic work in Bokong Nature Reserve in Lesotho, in collaboration with Prof Aliza le Roux from the Department of Zoology and Entomology and the Okinawa Institute of Science and Technology in Japan, as well as linking to BirdLife’s programme.

Global Mountain Safeguard Research in Southern Africa

Southern African links grew well in 2020 due to new mountain-focused contacts in Madagascar, Zambia, Malawi, and Réunion through the Global Mountain Safeguard Research (GLOMOS)-led Safeguarding Mountains book project, with Dr Clark being the editor of the African contribution. 

The ARU submitted several research proposals with members of the GLOMOS team, including on water security and civic society in Maloti-a-Phofung Local Municipality; climate change and water provisioning in the Maloti-Drakensberg; and a book (in process) on Phuthaditjhaba as an African mountain city.  

The ARU is also planning the first Southern African Mountain Conference (SAMC2022) in partnership with the AMRF and GLOMOS, which will take place from 14 to 17 March 2022. According to Dr Clark, they seek to draw a strong regional contribution for a better understanding of Southern African mountains as social-ecological systems. “We also aim to form a stronger science-policy-practitioner interface and community of practice for Southern African mountains,” he says. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept